Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30147% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Repligen's price to sales ratio was 12.4× on Nov 11, 2026, against 13.6× a year earlier. Over the last 5 years it ranged from 9.0× to 24.7×, with a median of 12.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.4× | −0.6 |
| 2025 | Dec 31, 2025 | 13.0× | +0.3 |
| 2024 | Dec 31, 2024 | 12.7× | −2.6 |
| 2023 | Dec 29, 2023 | 15.4× | +3.6 |
| 2022 | Dec 30, 2022 | 11.7× | −13.0 |
| 2021 | Dec 31, 2021 | 24.7× | −6.1 |
| 2020 | Dec 31, 2020 | 30.8× | +11.8 |
| 2019 | Dec 31, 2019 | 19.1× | +6.5 |
| 2018 | Dec 31, 2018 | 12.6× | −0.0 |
| 2017 | Dec 29, 2017 | 12.6× | +2.2 |
| 2016 | Dec 30, 2016 | 10.4× | −1.5 |
| 2015 | Dec 31, 2015 | 11.9× | +1.5 |
| 2014 | Dec 31, 2014 | 10.4× | −5.6 |
| 2013 | Dec 31, 2013 | 15.9× | +8.8 |
| 2012 | Dec 31, 2012 | 7.1× | +3.2 |
| 2011 | Dec 30, 2011 | 3.9× | −3.0 |
| 2010 | Dec 31, 2010 | 6.9× | – |
See a number that looks wrong?